Cargando…

Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study

Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and no human models exist at present. We harvested ALNs from ten BC patients, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrow‐McGee, Rachel, Procter, Julia, Owen, Julie, Woodman, Natalie, Lombardelli, Cristina, Kothari, Ashutosh, Kovacs, Tibor, Douek, Michael, George, Simi, Barry, Peter A, Ramsey, Kelvin, Gibson, Amy, Buus, Richard, Holgersen, Erle, Natrajan, Rachael, Haider, Syed, Shattock, Michael J, Gillett, Cheryl, Tutt, Andrew NJ, Pinder, Sarah E, Naidoo, Kalnisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065097/
https://www.ncbi.nlm.nih.gov/pubmed/31755096
http://dx.doi.org/10.1002/path.5367
_version_ 1783504996815339520
author Barrow‐McGee, Rachel
Procter, Julia
Owen, Julie
Woodman, Natalie
Lombardelli, Cristina
Kothari, Ashutosh
Kovacs, Tibor
Douek, Michael
George, Simi
Barry, Peter A
Ramsey, Kelvin
Gibson, Amy
Buus, Richard
Holgersen, Erle
Natrajan, Rachael
Haider, Syed
Shattock, Michael J
Gillett, Cheryl
Tutt, Andrew NJ
Pinder, Sarah E
Naidoo, Kalnisha
author_facet Barrow‐McGee, Rachel
Procter, Julia
Owen, Julie
Woodman, Natalie
Lombardelli, Cristina
Kothari, Ashutosh
Kovacs, Tibor
Douek, Michael
George, Simi
Barry, Peter A
Ramsey, Kelvin
Gibson, Amy
Buus, Richard
Holgersen, Erle
Natrajan, Rachael
Haider, Syed
Shattock, Michael J
Gillett, Cheryl
Tutt, Andrew NJ
Pinder, Sarah E
Naidoo, Kalnisha
author_sort Barrow‐McGee, Rachel
collection PubMed
description Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and no human models exist at present. We harvested ALNs from ten BC patients, and perfused them at 37 °C ex vivo for up to 24 h. Controlled autologous testing showed that ALNs remain viable after 24 h of ex vivo perfusion: haematoxylin and eosin‐stained histological appearance and proliferation (by Ki67 immunohistochemistry) did not change significantly over time for any perfused ALN compared with a control from time‐point zero. Furthermore, targeted gene expression analysis (NanoString PanCancer IO360 panel) showed that only 21/750 genes were differentially expressed between control and perfused ALNs (|log(2) FC| > 1 and q < 0.1): none were involved in apoptosis and metabolism, but rather all 21 genes were involved in immune function and angiogenesis. During perfusion, tissue acid–base balance remained stable. Interestingly, the flow rate increased (p < 0.001) in cancer‐replaced (i.e. metastasis occupied more than 90% of the surface area on multiple levels) compared to cancer‐free nodes (i.e. nodes with no metastasis on multiple sections). CXCL11 transcripts were significantly more abundant in cancer‐replaced nodes, while CXCL12 transcripts were significantly more abundant in cancer‐free nodes. These cytokines were also detected in the circulating perfusate. Monoclonal antibodies (nivolumab and trastuzumab) were administered into a further three ALNs to confirm perfusion efficacy. These drugs saturated the nodes; nivolumab even induced cancer cell death. Normothermic ALN perfusion is not only feasible but sustains the tumour microenvironment ex vivo for scientific investigation. This model could facilitate the identification of actionable immuno‐oncology targets. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
format Online
Article
Text
id pubmed-7065097
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70650972020-03-16 Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study Barrow‐McGee, Rachel Procter, Julia Owen, Julie Woodman, Natalie Lombardelli, Cristina Kothari, Ashutosh Kovacs, Tibor Douek, Michael George, Simi Barry, Peter A Ramsey, Kelvin Gibson, Amy Buus, Richard Holgersen, Erle Natrajan, Rachael Haider, Syed Shattock, Michael J Gillett, Cheryl Tutt, Andrew NJ Pinder, Sarah E Naidoo, Kalnisha J Pathol Original Papers Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and no human models exist at present. We harvested ALNs from ten BC patients, and perfused them at 37 °C ex vivo for up to 24 h. Controlled autologous testing showed that ALNs remain viable after 24 h of ex vivo perfusion: haematoxylin and eosin‐stained histological appearance and proliferation (by Ki67 immunohistochemistry) did not change significantly over time for any perfused ALN compared with a control from time‐point zero. Furthermore, targeted gene expression analysis (NanoString PanCancer IO360 panel) showed that only 21/750 genes were differentially expressed between control and perfused ALNs (|log(2) FC| > 1 and q < 0.1): none were involved in apoptosis and metabolism, but rather all 21 genes were involved in immune function and angiogenesis. During perfusion, tissue acid–base balance remained stable. Interestingly, the flow rate increased (p < 0.001) in cancer‐replaced (i.e. metastasis occupied more than 90% of the surface area on multiple levels) compared to cancer‐free nodes (i.e. nodes with no metastasis on multiple sections). CXCL11 transcripts were significantly more abundant in cancer‐replaced nodes, while CXCL12 transcripts were significantly more abundant in cancer‐free nodes. These cytokines were also detected in the circulating perfusate. Monoclonal antibodies (nivolumab and trastuzumab) were administered into a further three ALNs to confirm perfusion efficacy. These drugs saturated the nodes; nivolumab even induced cancer cell death. Normothermic ALN perfusion is not only feasible but sustains the tumour microenvironment ex vivo for scientific investigation. This model could facilitate the identification of actionable immuno‐oncology targets. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2019-12-22 2020-03 /pmc/articles/PMC7065097/ /pubmed/31755096 http://dx.doi.org/10.1002/path.5367 Text en © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Barrow‐McGee, Rachel
Procter, Julia
Owen, Julie
Woodman, Natalie
Lombardelli, Cristina
Kothari, Ashutosh
Kovacs, Tibor
Douek, Michael
George, Simi
Barry, Peter A
Ramsey, Kelvin
Gibson, Amy
Buus, Richard
Holgersen, Erle
Natrajan, Rachael
Haider, Syed
Shattock, Michael J
Gillett, Cheryl
Tutt, Andrew NJ
Pinder, Sarah E
Naidoo, Kalnisha
Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title_full Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title_fullStr Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title_full_unstemmed Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title_short Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study
title_sort real‐time ex vivo perfusion of human lymph nodes invaded by cancer (replicant): a feasibility study
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065097/
https://www.ncbi.nlm.nih.gov/pubmed/31755096
http://dx.doi.org/10.1002/path.5367
work_keys_str_mv AT barrowmcgeerachel realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT procterjulia realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT owenjulie realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT woodmannatalie realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT lombardellicristina realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT kothariashutosh realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT kovacstibor realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT douekmichael realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT georgesimi realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT barrypetera realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT ramseykelvin realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT gibsonamy realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT buusrichard realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT holgersenerle realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT natrajanrachael realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT haidersyed realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT shattockmichaelj realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT gillettcheryl realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT tuttandrewnj realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT pindersarahe realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy
AT naidookalnisha realtimeexvivoperfusionofhumanlymphnodesinvadedbycancerreplicantafeasibilitystudy